Tuesday, November 17, 2026
The Cancer News

AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER

Research

The volume and pace of cancer research, from preclinical studies to clinical trials and FDA approvals, can make it challenging to stay informed. This section highlights the latest developments and translates complex scientific concepts into clear, accessible insights for both healthcare professionals and the broader public.

Kidney Cancer in 2026: Real Benefit, Real Trade-offs in Adjuvant Therapy and First-Line Sequencing
Cancer Education · Research

Kidney Cancer in 2026: Real Benefit, Real Trade-offs in Adjuvant Therapy and First-Line Sequencing

By Alejandro Recio-Boiles, MD

Kidney cancer did not see the volume of practice-changing news that prostate or bladder cancer did this year, but three areas are worth attention

CAR-T, Bispecifics, or Transplant: Sequencing Relapsed Diffuse Large B-Cell Lymphoma Therapy in 2026
Cancer Education · Research

CAR-T, Bispecifics, or Transplant: Sequencing Relapsed Diffuse Large B-Cell Lymphoma Therapy in 2026

By Marin Xavier, MD

How to sequence relapsed diffuse large B-cell lymphoma therapy in 2026: CAR-T eligibility, bispecific antibody combinations like SUNMO and STARGLO, bridging strategies, and frontline changes ahead.

ADCs in Lung Cancer: Three Approved, Two More Coming, and a Toxicity Framework Every Oncologist Needs
Research · Cancer Education

ADCs in Lung Cancer: Three Approved, Two More Coming, and a Toxicity Framework Every Oncologist Needs

By Kim-son Nguyen, MD

Three antibody-drug conjugates are FDA-approved in NSCLC and two more are nearing approval in SCLC. Review HER2, cMET, and TROP2 indications, plus a toxicity framework for pneumonitis, neuropathy, and ocular effects.

Primary Refractory DLBCL: Choosing Between CAR-T and Bispecific Antibody Combinations
Cancer Education · Perspectives · Research

Primary Refractory DLBCL: Choosing Between CAR-T and Bispecific Antibody Combinations

By Autumn Jeong, MD

CAR-T cell therapy is the established standard second-line treatment for primary refractory or early relapsed diffuse large B-cell lymphoma, supported by mature, practice-defining trial data.

Small Cell Lung Cancer in 2026: Consolidation IO Is Standard, Tarlatamab Has Full Approval, and the Maintenance Era Has Arrived
Research · Cancer Education

Small Cell Lung Cancer in 2026: Consolidation IO Is Standard, Tarlatamab Has Full Approval, and the Maintenance Era Has Arrived

By Millie Das, MD

SCLC in 2026: consolidation durvalumab is standard in limited-stage disease, tarlatamab has full FDA approval, lurbinectedin maintenance is available, and antibody-drug conjugates are advancing in late-stage trials.

When a PARP Inhibitor Works but the Body Cannot Tolerate It: Severe Niraparib Toxicity in BRCA1-Mutated Ovarian Cancer
Research · Cancer Education

When a PARP Inhibitor Works but the Body Cannot Tolerate It: Severe Niraparib Toxicity in BRCA1-Mutated Ovarian Cancer

By Loan Retchless, ARNP

Updated pooled analyses of niraparib maintenance trials continue to show a clear progression-free survival benefit, particularly in BRCA-mutated and HRD-positive ovarian cancer, without a corresponding overall survival advantage

Upper GI Cancer Updates: Perioperative Immunotherapy and New HER2-Directed Options
Research · Cancer Education

Upper GI Cancer Updates: Perioperative Immunotherapy and New HER2-Directed Options

By Kayla Weiss Miranda, MD

Perioperative immunotherapy is the new standard for resectable gastric and GEJ cancer, and zanidatamab offers a new HER2-directed option for metastatic disease, based on MATTERHORN, NeoSUMMIT-01, and HERIZON-GEA-01.

Safe Delivery of CAR-T and Bispecific Therapy: Managing CRS and Building the Infrastructure Behind It
Cancer Education · Perspectives · Research

Safe Delivery of CAR-T and Bispecific Therapy: Managing CRS and Building the Infrastructure Behind It

By Justine Wilson-Miller, PharmD, BCOP

Centers manage cytokine release syndrome (CRS) very differently, and patient safety depends on the system, not only the drug.

Financial Toxicity and Access to Oral Chemotherapy: Prior Authorization, Specialty Pharmacy Steering, and the Importance of Advocacy
Cancer Education · Research · Perspectives

Financial Toxicity and Access to Oral Chemotherapy: Prior Authorization, Specialty Pharmacy Steering, and the Importance of Advocacy

By Sarah Profitt, PharmD, MMHC, BCOP

Prior authorization requirements and specialty pharmacy steering by payors delay the start of oral anticancer therapy, interrupt established treatment and worsen adherence.

The Shifting Playbook for Relapsed Large B-Cell Lymphoma: From Transplant to CAR T and Beyond
Cancer Education · Research

The Shifting Playbook for Relapsed Large B-Cell Lymphoma: From Transplant to CAR T and Beyond

By Krishna Rekha Moturi, MBBS

Second-line care for relapsed large B-cell lymphoma has moved decisively away from salvage chemotherapy and transplant toward CAR T-cell therapy for patients with early relapse.

Page 1 of 20
(198 articles)
PreviousNext